Valuation: Gilead Sciences, Inc.

Market Cap 21TCr 19TCr 17TCr 15TCr 29TCr 19,67700Cr 30TCr 2,03500Cr 82TCr 10,38500Cr 78TCr 76TCr 32,91700Cr P/E 2026 *
-40.1x
P/E 2027 * 20.3x
Enterprise Value 23TCr 20TCr 19TCr 17TCr 32TCr 21,69200Cr 33TCr 2,24300Cr 90TCr 11,44900Cr 86TCr 84TCr 36,28800Cr EV / Sales 2026 *
7.32x
EV / Sales 2027 * 6.54x
Free-Float
99.86%
Yield 2026 *
1.97%
Yield 2027 * 2.01%
1 day+3.44%
1 week+9.05%
Current month+1.72%
1 month+20.04%
3 months+28.36%
6 months+30.84%
Current year+41.45%
1 week 160.86
Extreme 160.86
175.65
1 month 142.6
Extreme 142.5982
175.65
Current year 116.88
Extreme 116.88
175.65
1 year 116.88
Extreme 116.88
175.65
3 years 62.07
Extreme 62.07
175.65
5 years 57.16
Extreme 57.165
175.65
10 years 56.56
Extreme 56.56
175.65
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Sell

Executive/Senior Manager

-3,000 0.0002%
15/10/26 Sell

Chief Financial Officer

-3,000 0.0002%
01/10/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+3.56%+9.05%+41.15%+113.96% 21TCr
+1.51%+11.14%+57.89%+140.57% 1,25500Cr
+2.60%+0.41%+45.64%+79.39% 64TCr
+1.17%+1.22%+34.08%+105.01% 51TCr
+1.25%-0.73%+49.96%+66.94% 38TCr
+2.46%+5.18%+76.75%+42.06% 36TCr
+2.10%+3.90%+32.30%+59.38% 30TCr
+1.92%+9.87%+11.94%+36.47% 29TCr
+3.73%+6.00%+61.42%+75.54% 25TCr
+5.57%+11.84%-9.52%-59.32% 18TCr
Average +2.43%+3.06%+40.16%+66.00% 43.64TCr
Weighted average by Cap. +2.03%+3.91%+46.04%+87.36%

Financials

2026 *2027 *
Net sales 3.13TCr 2.8TCr 2.57TCr 2.33TCr 4.38TCr 2,96400Cr 4.49TCr 31TCr 12TCr 1,56400Cr 12TCr 11TCr 4,95800Cr 3.35TCr 3TCr 2.75TCr 2.5TCr 4.7TCr 3,17800Cr 4.81TCr 33TCr 13TCr 1,67700Cr 13TCr 12TCr 5,31700Cr
Net income -509.06Cr -454.8Cr -417.76Cr -379.41Cr -712.5Cr -48TCr -730.4Cr -4.99TCr -2.01TCr -25TCr -1.91TCr -1.87TCr -81TCr 1.06TCr 947.71Cr 870.53Cr 790.62Cr 1.48TCr 1,00500Cr 1.52TCr 10TCr 4.18TCr 53TCr 3.98TCr 3.9TCr 1,68100Cr
Net Debt 2.13TCr 1.9TCr 1.75TCr 1.59TCr 2.98TCr 2,01500Cr 3.05TCr 21TCr 8.38TCr 1,06400Cr 7.98TCr 7.81TCr 3,37100Cr 1.16TCr 1.04TCr 952.9Cr 865.43Cr 1.63TCr 1,10000Cr 1.67TCr 11TCr 4.58TCr 58TCr 4.36TCr 4.27TCr 1,84000Cr
Projected Income Statement - Annual - Gilead Sciences, Inc.
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
04/26/04 $173.43 +3.56% 31,30,147
03/26/03 $167.47 -1.68% 66,06,702
02/26/02 $170.33 -0.21% 88,76,067
30/26/30 $170.68 +3.06% 1,14,27,256
29/26/29 $165.61 +4.03% 84,31,613
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Gilead Sciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
167.47USD
Average target price
172.50USD
Spread / Average Target
+3.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gilead Sciences, Inc.
  1. Stock Market
  2. Stocks
  3. GILD Stock